Trial Profile

A phase III pivotal, multicenter, double-blind, randomized, placebo-controlled study of milnacipran for the treatment of fibromyalgia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 23 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Milnacipran (Primary)
Indications Fibromyalgia; Musculoskeletal pain
Focus Registrational; Therapeutic Use
Sponsors Forest Laboratories

Most Recent Events

24 Oct 2020 Results of two large analgesic clinical trials (NCT00098124 and NCT00436033) for the treatment of fibromyalgia to evaluate the utility of different pain indices for detecting intervention effects, published in the Journal of Pain
20 May 2009 Additional reference added (1132643) relating to published results from 162nd Annual Meeting of the American Psychiatric Association.
07 May 2009 Results presented at the 28th Annual Scientific Meeting of the American Pain Society (APS 2009).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com